Mabion
  • Company
    • About us
      • History
      • Leaderships
      • Team
      • EU grants
      • Requests for Proposal
      • Sustainability – ESG
      • Bussines strategy
      • Quality policy
      • Virtual Tour
    • Investors
      • Corporate documents
      • Shareholders and shares
      • Periodic reports
      • Current reports
      • Sustainability reports
      • Corporate governance at Mabion
      • Financial data
      • For Investors
      • Calendar
  • Science News
  • Resources

Monoclonal antibody

Breast self-examination Breast Cancer Awareness Month - October 2026 Breast Cancer Targeted Therapies

Breast Cancer Targeted Therapies and Immunotherapies

Antibody-drug conjugates, Biologics, Cancer, Monoclonal antibody
monoclonal antibody production

Monoclonal Antibody Production in Modern Biologics Manufacturing 

GMP, Manufacturing, Monoclonal antibody
PD-1-Antibody-Development-Programs-for-Cancer-Immunotherapy

PD-1 Antibody Development Programs for Cancer Immunotherapy

Bispecific antibody, Cancer, Drug substance, Manufacturing, Monoclonal antibody
High-yield Monoclonal Antibodies Manufacturing Platform Approach cover

High-yield mAbs Manufacturing Platform Approach

Drug substance, Mabion, Manufacturing, Monoclonal antibody
innovative biologics 2026

Innovative Biologics Expected Approvals in 2026

Antibody-drug conjugates, Biologics, Bispecific antibody, Clinical trials, EMA, FDA, Monoclonal antibody, Vaccines
Monoclonal Antibody Prophylaxis for Infectious Diseases

Monoclonal Antibody Prophylaxis for Infectious Diseases – Passive Immunization and Prevention

Monoclonal antibody, Vaccines
From Research to Release: Mapping Mabion’s Full Analytical Lifecycle for Monoclonal Antibodies

From Research to Release: Mapping Mabion’s Full Analytical Lifecycle for Monoclonal Antibodies 

Analytics, Mabion, Monoclonal antibody
antibodies development best practices

Antibodies Development Best Practices for CDMO Collaboration

Drug development, Manufacturing, Monoclonal antibody
Innovative biologics that are expected to be approved in 2025

Innovative Biologics – Expected Drug Approvals in 2025

Antibody-drug conjugates, Biologics, Bispecific antibody, Clinical trials, EMA, FDA, Monoclonal antibody, Vaccines
1 2 Next

Contact

Find out how we may support your business.

bd@mabion.eu

Mabion

gen. Mariana Langiewicza 60
95-050 Konstantynów Łódzki
Poland

+48 42 207 78 90

    Mabion
    • Privacy policy
    • CDMO
    • Media kit
    • Press releases
    • Events

    This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. HTML Sitemap

    Powered by

    Veneo